A new Canadian study reports that dopamine agonist withdrawal syndrome (DAWS) is a potentially disabling complication associated with dopamine agonist use in patients with Parkinson’s disease (Pondal et al. J Neurol Neurosurg Psychiatry 2012; epublished August 29, 2012).
Latest News
Aubade for Aubagio: FDA approves teriflunomide in RRMS
October 24, 2012The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada.
Small, short-term benefit with physiotherapy in PD: meta-analysis
October 24, 2012A Cochrane meta-analysis has examined 33 trials (n=1,518) to determine the benefits of physiotherapy versus no physiotherapy in patients with Parkinson’s disease (Tomlinson et al. Cochrane Database Syst Rev 2012 Aug 15;8:CD002817). Interventions included general physiotherapy, exercise, treadmill training, dance and martial arts.
BG-12: Updated data from phase III studies
August 29, 2012REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – The efficacy and safety of the oral fumarate BG-12 has been evaluated in the phase III studies DEFINE and CONFIRM (see BG-12 in RRMS: DEFINE trial, NeuroSens, October 21, 2011; CONFIRM – Second phase III trial results for BG-12, NeuroSens, November 30, 2011). New data from both trials were presented at AAN.